Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Relugolix for treating hormone-sensitive prostate cancer as of August 2024

MARA Rating Company December 16, 2025

Ryeqo for treating symptoms of endometriosis as of April 2025

MARA Rating Company December 16, 2025

Remdesivir / veklury for treating COVID-19 as of May 2024

MARA Rating Company December 16, 2025

Kisqali / ribociclib for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as of March 2021

MARA Rating Company December 16, 2025

Rimegepant / vydura for preventing migraine as of July 2023

MARA Rating Company December 16, 2025

Pemaryze / pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement as of August 2021

MARA Rating Company December 16, 2025

Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea as of March 2022

MARA Rating Company December 16, 2025

Polatuzumab vedotin for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) as of March 2023

MARA Rating Company December 16, 2025

Ponesimod / ponvory for treating relapsing-remitting multiple sclerosis as of February 2022

MARA Rating Company December 16, 2025

Gavreto / pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer as of August 2022

MARA Rating Company December 16, 2025